Connect your AI

Altimmune ALT Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Wave Life SciencesWVE

——

Beam TherapeuticsBEAM

——

Corcept TherapeuticsCORT

——

Other financials

Income statement

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Altimmune's proceeds from issuance of common stock relating to employee stock plans?: Altimmune (ALT) reported proceeds from issuance of common stock relating to employee stock plans of $177K in Q1 2026.
How has Altimmune's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Altimmune's proceeds from issuance of common stock relating to employee stock plans increased by 4.1% year-over-year, from $170K to $177K.